Intuitive Surgical Reports 21% Revenue Growth for 2025

Reuters
01/14
Intuitive Surgical Reports 21% Revenue Growth for 2025

Intuitive Surgical Inc. announced preliminary, unaudited financial and operational results for the fourth quarter and full year 2025. Worldwide procedures using the company’s da Vinci and Ion platforms grew approximately 18% compared to the fourth quarter of 2024, with da Vinci procedures increasing by 17% and Ion procedures by 44%. Average da Vinci system utilization rose by 4% year-over-year in the fourth quarter, attributed primarily to increased adoption of the da Vinci 5 system in the U.S. and growth in markets outside the U.S. During 2025, Intuitive placed 1,721 da Vinci surgical systems, up from 1,526 in 2024. Of these, 870 were da Vinci 5 systems, compared to 362 in 2024. The company placed 195 Ion endoluminal systems in 2025, compared to 271 in the prior year. Preliminary revenue for the fourth quarter of 2025 was approximately $2.87 billion, representing a 19% increase from $2.41 billion in the same period of 2024. Preliminary full-year revenue for 2025 was approximately $10.06 billion, a 21% increase from $8.35 billion in 2024. Fourth quarter 2025 expenses included a $70 million contribution to the Intuitive Foundation, compared to $45 million in the fourth quarter of 2024. The company reported that more than 3.1 million da Vinci procedures were performed during 2025. Additional unaudited preliminary revenue and procedure information is available in the Investor Relations section of the Intuitive website. The company plans to discuss full financial results in detail during its scheduled conference call on January 22, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intuitive Surgical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9625439-en) on January 14, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10